Evidence map›Paper›PMID 37926523›Full record

ArticleJournal of atherosclerosis and thrombosis2024

Role of Small Dense Low-density Lipoprotein Cholesterol in Cardiovascular Events in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Receiving Statin Treatment.

Takayuki Yamaji, Takahiro Harada, Masato Kajikawa, Tatsuya Maruhashi, Shinji Kishimoto, Farina Mohamad Yusoff, Kazuaki Chayama, Chikara Goto, Ayumu Nakashima, Hirofumi Tomiyama and 22 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of atherosclerosis and thrombosis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 2 countries.

Takayuki YamajiDepartment of Cardiovascular Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takahiro HaradaDepartment of Cardiovascular Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Masato KajikawaDivision of Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.
Tatsuya MaruhashiDepartment of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Shinji KishimotoDepartment of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Farina Mohamad YusoffDepartment of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Kazuaki ChayamaDepartment of Gastroenterology and Metabolism, Institute of Biomedical and Health Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Chikara GotoDepartment of Physical Therapy, Hiroshima International University, Hiroshima, Japan.
Ayumu NakashimaDivision of Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.
Hirofumi TomiyamaDepartment of Cardiology, Tokyo Medical University, Tokyo, Japan.
Bonpei TakaseDivision of Biomedical Engineering, National Defense Medical College Research Institute, Tokorozawa, Japan.
Takahide KohroDepartment of Clinical Informatics, Jichi Medical University School of Medicine, Tochigi, Japan.
Toru SuzukiCardiovascular Medicine, University of Leicester, Leicester, UK.
Tomoko IshizuCardiovascular Division, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan.
Shinichiro UedaDepartment of Clinical Pharmacology and Therapeutics, University of the Ryukyu School of Medicine, Okinawa, Japan.
Tsutomu YamazakiDepartment of Clinical Epidemiology and Systems, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Tomoo FurumotoDepartment of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
Kazuomi KarioDivision of Cardiovascular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
Teruo InoueDepartment of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan.
Kentaro WatanabeDepartment of Neurology, Hematology, Metabolism, Endocrinology and Diabetelogy (DNHMED), Yamagata University School of Medicine, Yamagata, Japan.
Yasuhiko TakemotoDepartment of Internal Medicine and Cardiology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Takuzo HanoDepartment of Medical Education and Population-based Medicine, Postgraduate School of Medicine, Wakayama Medical University, Wakayama, Japan.
Masataka SataDepartment of Cardiovascular Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.
Yutaka IshibashiDepartment of General Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
Koichi NodeDepartment of Cardiovascular and Renal Medicine, Saga University, Saga, Japan.
Koji MaemuraDepartment of Cardiovascular Medicine, Course of Medical and Dental Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Yusuke OhyaThe Third Department of Internal Medicine, University of the Ryukyus, Okinawa, Japan.
Taiji FurukawaDepartment of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Hiroshi ItoDepartment of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Akira YamashinaDepartment of Cardiology, Tokyo Medical University, Tokyo, Japan.
Shinji KobaDepartment of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan.
Yukihito HigashiDivision of Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan.
Hiroshima University · JPHiroshima University Hospital · JPJichi Medical University · JPTokyo Medical University · JPUniversity of the Ryukyus · JPDokkyo Medical University · JPHiroshima International University · JPHokkaido University · JPNagasaki University · JPNational Defense Medical College · JPOkayama University · JPSaga University · JPShimane University · JPShowa University · JPTeikyo University · JPThe University of Tokyo · JPTokushima University · JPTokyo Metropolitan University · JPUniversity of Leicester · GBUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThere is little information on the relationships of serum small dense low-density lipoprotein cholesterol (sdLDL-C) levels and serum triglyceride (TG) levels with cardiovascular events in patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM) who are receiving statins. The aim of this study was to evaluate the relationships of serum TG levels and sdLDL-C levels as residual risks for cardiovascular events in patients with CAD and type 2 DM who were being treated with statins.

methodsThe subjects were divided into four groups based on TG levels and sdLDL-C levels: sdLDL-C of ＜40.0 mg/dL and TG of ＜150 mg/dL, sdLDL-C of ≥ 40.0 mg/dL and TG of ＜150 mg/dL, sdLDL-C of ＜40.0 mg/dL and TG of ≥ 150 mg/dL, and sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL. During a median follow-up period of 1419 days, cardiovascular events occurred in 34 patients.

resultsThe incidences of cardiovascular events were significantly higher in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of ＜150 mg/dL and in patients with sdLDL-C of ≥ 40.0 mg/dL and TG of ≥ 150 mg/dL, but not in patients with sdLDL-C of ＜40.0 mg/dL and TG of ≥ 150 mg/dL, than in patients with sdLDL-C of ＜40.0 mg/dL and TG of ＜150 mg/dL.

conclusionsUnder the condition of treatment with statins, patients with CAD and type 2 DM who had sdLDL-C levels of ≥ 40.0 mg/dL had a high risk for cardiovascular events even though serum TG levels were controlled at ＜150 mg/dL.

Indexed as

Coronary Artery DiseaseDiabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLHumansRisk FactorsTriglyceridesCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsTriglyceridesCardiovascular eventsSmall dense low-density lipoprotein cholesterolStatinTriglyceridesType 2 diabetes mellitus

Identifiers

PMID37926523
PMCPMC10999715
OpenAlexW4388240789

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.